CBDT's circular denying deduction on 'freebees' given to medical professionals by pharmaceutical companies is violation of MCI Regulations

February 23, 2018

In brief

In a recent decision, the Pune bench of the Income-tax Appellate Tribunal (Tribunal) observed that the circular issued by Central Board of Direct Taxes (CBDT), denying the claim of freebees given to medical practitioners as expenses, was enlarging the scope of the provisions of Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 read with subsequent circular issued by Medical Council of India (MCI).

The Tribunal has held that the CBDT's circular is without any enabling notification or circular of the MCI and violates the MCI Regulations. Hence, held that pharmaceutical companies are outside the scope of circulars issued by the MCI.

In detail

Facts

- The taxpayer is a pharmaceutical company engaged in the manufacture of generic drugs.
- The taxpayer had incurred certain sales promotion expenses which included expenses incurred for providing gifts and other benefits to the medical practitioners.
- MCI through a circular³ amended the MCI Regulations and imposed prohibition on medical practitioner and their

- professional associations from taking any gift, travel facility, hospitality, cash or monetary grant from the pharmaceutical and allied health sector industries.
- The CBDT through a circular² clarified that freebees given to medical practitioners and their professional associations was in violation of the provisions of MCI Regulations and should be inadmissible under section 37(1) of the Income-tax Act, 1961 (the Act).
- The tax officer (TO) placed reliance on the aforesaid

- circulars and denied the claim of the taxpayer to the extent of gifts and other benefits provided to medical practitioners.
- On appeal, the first appellate authority upheld the TO's order.

Issue before the Tribunal

- Whether the circular issued by the MCI prohibiting the medical practitioners from taking any gift is applicable to pharmaceutical companies?
- Whether the circular issued by CBDT is consistent with the circular issued by MCI?

³ Circular of Medical Council of India dated 10 December, 2009



¹ ITA No. 1532/ PUN/ 2015

² Circular No. 5/ 2012 dated 1 August, 2012

Taxpayer's contentions

- The taxpayer contended that the circular issued by the MCI does not indicate the violation of any code of conduct with respect to pharmaceutical industry (as donor).
- The circular issued by the CBDT expanding the scope of circular of MCI to pharmaceutical companies is not proper and unsustainable in law.
- The taxpayer relied on decisions₄ wherein it was held that pharmaceutical companies are outside the scope of the circular issued by the MCI, despite the CBDT circular roping-in pharmaceutical companies.
- Further, the taxpayer also contended that the circular issued by CBDT does not apply retrospectively.

Revenue's contentions

 The Revenue contended that the pharmaceutical companies giving gifts also violated the code of conduct set by the CBDT circular as well as by the

MCI.

 The Revenue also placed reliance on the decision of Himachal Pradesh High Courts.

Tribunal's decision

- The Tribunal noted that the issue was squarely covered by the decisions relied on by the taxpayer.
- The Tribunal observed that in the absence of a specific mention about the applicability of the circular to pharmaceutical companies, it was quite apparent that the MCI Regulations are were meant to be followed and adhered by medical practitioners/ doctors alone.
- The Tribunal also observed that if a pharmaceutical company was not prohibited from giving freebees to medical practitioners, then the provisions of section 37(1) of the Act, could not be applied to it.
- The MCI has itself admitted before the Delhi High Court6 that its Regulations have

- jurisdiction to take action only against medical practitioners and not against the healthcare sector industry.
- Circulars issued by the CBDT must confirm the tax laws and provide administrative relief or clarify the provisions of law, and cannot impose a burden on the taxpayer.

The takeaways

- The Tribunal reaffirms that the pharmaceutical companies are outside the ambit of circular of CBDT.
- Expenses incurred by pharmaceutical companies in providing freebees to medical practitioners are not subject to disallowance under section 37(1) of the Act.
- CBDT cannot impose a new burden by enlarging the scope of a different regulation passed under a different law.

Let's talk

For a deeper discussion of how this issue might affect your business, please contact your local PwC advisor

^{4 163} ITD 10 (Mum. ITAT) and 89 taxmann.com 249 (Mum. ITAT)

Our Offices

Ahmedabad

1701, 17th Floor, Shapath V, Opp. Karnavati Club, S G Highway, Ahmedabad – 380051 Gujarat +91-79 3091 7000

Hyderabad

Plot no. 77/A, 8-2-624/A/1, 4th Floor, Road No. 10, Banjara Hills, Hyderabad – 500034, Telangana +91-40 44246000

Gurgaon

Building No. 10, Tower - C 17th & 18th Floor, DLF Cyber City, Gurgaon – 122002 Haryana +91-124 330 6000

Bengaluru

6th Floor Millenia Tower 'D' 1 & 2, Murphy Road, Ulsoor, Bengaluru – 560 008 Karnataka +91-80 4079 7000

Kolkata

56 & 57, Block DN. Ground Floor, A- Wing Sector - V, Salt Lake Kolkata – 700 091, West Bengal +91-033 2357 9101/ 4400 1111

Pune

7th Floor, Tower A - Wing 1, Business Bay, Airport Road, Yerwada, Pune – 411 006 Maharashtra +91-20 4100 4444

Chennai

8th Floor Prestige Palladium Bayan 129-140 Greams Road Chennai – 600 006 Tamil Nadu +91 44 4228 5000

Mumbai

PwC House Plot No. 18A, Guru Nanak Road(Station Road), Bandra (West), Mumbai – 400 050 Maharashtra +91-22 6689 1000

For more information

Contact us at pwctrs.knowledgemanagement@in.pwc.com

About PwC

At PwC, our purpose is to build trust in society and solve important problems. We're a network of firms in 157 countries with more than 223,000 people who are committed to delivering quality in assurance, advisory and tax services. Find out more and tell us what matters to you by visiting us at www.pwc.com.

In India, PwC has offices in these cities: Ahmedabad, Bengaluru, Chennai, Delhi NCR (Gurgaon), Hyderabad, Kolkata, Mumbai and Pune. For more information about PwC India's service offerings, visit www.pwc.com/in

PwC refers to the PwC International network and/or one or more of its member firms, each of which is a separate, independent and distinct legal entity. Please see www.pwc.com/structure for further details.

©2018 PwC. All rights reserved

Follow us on:









For private circulation only

This publication has been prepared for general guidance on matters of interest only, and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, PwCPL, its members, employees and agents accept no liability, and disclaim all responsibility, for the consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it. Without prior permission of PwCPL, this publication may not be quoted in whole or in part or otherwise referred to in any documents.

© 2018 PricewaterhouseCoopers Private Limited. All rights reserved. In this document, "PwC" refers to PricewaterhouseCoopers Private Limited (a limited liability company in India having Corporate Identity Number or CIN: U74140WB1983PTC036093), which is a member firm of PricewaterhouseCoopers International Limited (PwCIL), each member firm of which is a separate legal entity.